| Size | Price | Stock | Qty |
|---|---|---|---|
| 500mg |
|
||
| 1g |
|
||
| 5g |
|
||
| 10g |
|
||
| 25g |
|
||
| 50g |
|
||
| Other Sizes |
|
Purity: ≥98%
PMSF (full name: Phenylmethanesulfonyl fluoride) is a potent and irreversible inhibitor of serine/cysteine protease, which includes chymotrypsin, thrombin, and trypsin. It may also have analgesic properties. PMSF exhibited antinociception, hypothermia, and immobility as cannabinoid effects.
| Targets |
cysteine protease; chymotrypsin
|
|---|---|
| ln Vitro |
PMSF quickly inactivates purified chymotrypsin from the human pancreas, while human trypsin is less susceptible to inhibition by PMSF. Acetylcholinesterase from human red blood cells is also quickly inhibited by PMSF. (Source: ) At 2 mM, PMSF treatment almost completely inhibits carbachol-stimulated inositol incorporation into phosphatidylinositol (PI) of the longitudinal smooth muscle of the guinea pig ileum. It has no effect on potassium-stimulated inositol incorporation.PMSF causes a temporary inhibition of contraction by both potassium and carbachol, in contrast to its specific inhibition of carbachol-stimulated phosphoinositide turnover.[3] In Trypanosoma brucei, it has been demonstrated that PMSF inhibits the addition of ethanolamine phosphate to glycosylphosphatidylinositol (GPI) intermediates. Moreover, PMSF prevents T. brucei from acylating the inositol residue of GPI intermediates in the bloodstream. In procyclic forms of T. brucei, PMSF inhibits the addition of ethanolamine phosphate and inositol acylation, but not in mammalian HeLa cells. In [4] As an 8-fold higher BSF concentration is required to achieve even a 6-fold slower inactivation than that using PMSF, PMSF is the more reactive inactivator of mouse acetylcholinesterase (AChE). (7)
|
| ln Vivo |
In Sprague-Dawley rats, intraperitoneal injection of PMSF results in dose-dependent analgesia. In rats, PMSF dramatically increases the analgesic effect of beta-endorphin (END).[2] With ED50 values of 86 mg/kg, 224 mg/kg, and 206 mg/kg, respectively, mice receiving intraperitoneal injections of PMSF display a range of cannabinoid effects, including antinociception, hypothermia, and immobility. Anandamide increases its effects on tail-flick response (antinociception), spontaneous activity, and mobility by five, ten, and eight times, respectively, when pretreated with an inactive dose of PMSF (30 mg/kg).[5] When administered 12 hours before PSP, PMSF completely protects hens from organophosphorus ester-induced delayed neuropathy (OPIDN); however, when administered 4 hours after PSP, PMSF intensifies its neurotoxic effects.[6] Five minutes after injecting 1 or 10 mg/kg of 3H-anandamide, pretreatment with PMSF (30 mg/kg, i.p.) elevates anandamide levels in the brain in comparison to the injection of 3H-anandamide plus vehicle.[8] Hens protected against the development of organophosphate-induced delayed neuropathy (OPIDN) are protected by pretreatment with PMSF, which inhibits the degradation of neurofilament (NF) induced by tri-ortho-cresyl phosphate (TOCP).[9] PMSF administration increases the distinct cannabimimetic effects of anandamide (AEA) or Δ(9)-tetrahydrocannabinol (THC) in ICR mice by blocking the fatty acid amide hydrolase enzyme.[10]
|
| Enzyme Assay |
Phenylmethanesulfonyl fluoride (PMSF) (2 mM), a putative inhibitor of phosphatidylinositol-specific phospholipase C, almost completely inhibited carbachol-stimulated inositol incorporation into phosphatidylinositol (PI) of longitudinal smooth muscle of guinea pig ileum, while it had no effect on potassium-stimulated inositol incorporation. This suggests that the two stimuli may affect phosphoinositide turnover by different mechanisms, distinguishable by PMSF. In contrast to its specific inhibition of carbachol-stimulated phosphoinositide turnover, PMSF produced a transient inhibition of contraction by both carbachol and potassium. The non-selective effect of PMSF on contraction suggests that it is not the result of its inhibitory effect on phosphoinositide breakdown. PMSF (2 mM) inhibited carbachol-stimulated inositol phosphate accumulation in the presence of Li+ by only 15%-19%, indicating that PMSF inhibition of phosphoinositide turnover was not due to its inhibition of phosphoinositide phosphodiesterase, but to one or more steps following phosphoinositide breakdown[3].
|
| Cell Assay |
PMSF blocks T. brucei's ability to acylate the inositol residue of GPI intermediates in the bloodstream. Though it does not prevent fatty acid remodeling in vitro, PMSF inhibits the formation of glycolipid C. Hela cells are not affected by PMSF, but procyclic trypanosomes are inhibited in GPI acylation and ethanolamine phosphatp addition.
|
| Animal Protocol |
In the experiment, male ICR mice weighing between 18 and 25 g are employed. After dissolving PMSF in sesame oil, 0.1 mL/10 g b.wt. of the solution is injected intraperitoneally. Ten minutes should always elapse between intravenous anandamide or vehicle injections before administering PMSF. Overnight, food and water are not provided to the mice as they become used to the assessment area. Each animal is assessed as follows after receiving anandamide intravenously or a vehicle: tail-flick latency (antinociception) response at 5 minutes and spontaneous (locomotor) activity at 5 to 15 minutes; or core (rectal) temperature at 5 minutes and ring-immobility (catalepsy) at 5 to 10 minutes.
|
| References | |
| Additional Infomation |
Phenylmethanesulfonyl fluoride is an acyl fluoride with phenylmethanesulfonyl as the acyl group. It has a role as a serine proteinase inhibitor. It is functionally related to a phenylmethanesulfonic acid.
Phenylmethylsulfonyl fluoride has been reported in Ixora coccinea with data available. An enzyme inhibitor that inactivates IRC-50 arvin, subtilisin, and the fatty acid synthetase complex. See also: 4-Toluenesulfonyl fluoride (annotation moved to). |
| Molecular Formula |
C7H7FO2S
|
|
|---|---|---|
| Molecular Weight |
174.19
|
|
| Exact Mass |
174.015
|
|
| Elemental Analysis |
C, 48.27; H, 4.05; F, 10.91; O, 18.37; S, 18.41
|
|
| CAS # |
329-98-6
|
|
| Related CAS # |
|
|
| PubChem CID |
4784
|
|
| Appearance |
White to off-white solid powder
|
|
| Density |
1.3±0.1 g/cm3
|
|
| Boiling Point |
285.7±19.0 °C at 760 mmHg
|
|
| Melting Point |
92-95 °C
|
|
| Flash Point |
126.6±21.5 °C
|
|
| Vapour Pressure |
0.0±0.6 mmHg at 25°C
|
|
| Index of Refraction |
1.522
|
|
| LogP |
2.33
|
|
| Hydrogen Bond Donor Count |
0
|
|
| Hydrogen Bond Acceptor Count |
3
|
|
| Rotatable Bond Count |
2
|
|
| Heavy Atom Count |
11
|
|
| Complexity |
199
|
|
| Defined Atom Stereocenter Count |
0
|
|
| SMILES |
O=S(CC1=CC=CC=C1)(F)=O
|
|
| InChi Key |
YBYRMVIVWMBXKQ-UHFFFAOYSA-N
|
|
| InChi Code |
InChI=1S/C7H7FO2S/c8-11(9,10)6-7-4-2-1-3-5-7/h1-5H,6H2
|
|
| Chemical Name |
phenylmethanesulfonyl fluoride
|
|
| Synonyms |
|
|
| HS Tariff Code |
2934.99.9001
|
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
|
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
|
|||
|---|---|---|---|---|
| Solubility (In Vivo) |
Solubility in Formulation 1: ≥ 2 mg/mL (11.48 mM) (saturation unknown) in 10% DMSO + 40% PEG300 + 5% Tween80 + 45% Saline (add these co-solvents sequentially from left to right, and one by one), clear solution.
For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 20.0 mg/mL clear DMSO stock solution to 400 μL PEG300 and mix evenly; then add 50 μL Tween-80 to the above solution and mix evenly; then add 450 μL normal saline to adjust the volume to 1 mL. Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH₂ O to obtain a clear solution. Solubility in Formulation 2: ≥ 2 mg/mL (11.48 mM) (saturation unknown) in 10% DMSO + 90% (20% SBE-β-CD in Saline) (add these co-solvents sequentially from left to right, and one by one), clear solution. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 20.0 mg/mL clear DMSO stock solution to 900 μL of 20% SBE-β-CD physiological saline solution and mix evenly. Preparation of 20% SBE-β-CD in Saline (4°C，1 week): Dissolve 2 g SBE-β-CD in 10 mL saline to obtain a clear solution. View More
Solubility in Formulation 3: ≥ 2 mg/mL (11.48 mM) (saturation unknown) in 10% DMSO + 90% Corn Oil (add these co-solvents sequentially from left to right, and one by one), clear solution. Solubility in Formulation 4: 20 mg/mL (114.82 mM) in Corn Oil (add these co-solvents sequentially from left to right, and one by one), clear solution; with ultrasonication. |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 5.7409 mL | 28.7043 mL | 57.4086 mL | |
| 5 mM | 1.1482 mL | 5.7409 mL | 11.4817 mL | |
| 10 mM | 0.5741 mL | 2.8704 mL | 5.7409 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
COA